Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Show detailsHide details
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Curis, Inc.
A clinical-stage biotechnology company in Lexington, Massachusetts, developing emavusertib, an oral pill for blood cancers like primary central nervous system lymphoma and chronic lymphocytic leukemia. Formed in 2000 from the merger of three Boston-area biotech firms, its logo carries a musical fermata—a symbol that holds a note—reflecting its goal of prolonging life and curing cancer. Curis also helped develop Erivedge, an approved treatment for advanced basal cell carcinoma.
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and Exhibits
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 Submission of Matters to a Vote of Security Holders
3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits